December 30, 2004 - 9:39pm
From Novartis Pharma AG:
December 23, 2004 – Novartis Pharma AG announced that the U.S. Food and Drug Administration (FDA) has approved Enablex (darifenacin) extended-release tablets (7.5mg and 15mg) for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and frequency. Enablex, a once-daily medication, is expected to launch in the U.S. in early 2005.
Complete press release can be found at Novartis
Prescribing information is available at Enablex
Pill Identification - Enablex (darifenacin):
The 7.5-mg tablet is round and white-colored with DF on one side and 7.5 on the other side.
The 15-mg tablet is round and peach-colored with DF on one side and 15 on the other side.
For more information, please see the Enablex website.
Updated 03-08-06
